TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Episodes of Acute-on-Chronic Liver Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenotypic description of idiopathic lung disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Spontaneous recovery or liver transplant or death
Endpoint domain: Mortality/survival
Primary endpoint: Change in C-peptide IAUC (0-4hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Gravity induced change in movement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gravity induced change in peak velocity of the hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gravity induced change in the maximum grip aperture of the hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gravity induced change in the initial force applied by the hand on the grasped object
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in agitation from baseline to 2 hours post injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients willing to participate in randomized trial
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in best spectacle-corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean recovery time after propofol sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of specific brain areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in serum Bioactive IGF-I and IGFBP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in plasma Interleukin-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in serum hsCRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Prolonged Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Debriding effect on chronic lower leg ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Non-adherence days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pharmacokinetic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Number of Days of Unscheduled Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Early Postoperative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effects on the QTc Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of bacterial pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Activity of the ventral striatum during reward expectation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Performance in reward based learning tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of subjects who complete the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pulse pressure variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Gross Motor Function Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of fruit and vegetable purchases
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of matured oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: number of good quality embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Ratio of ATP 5+ to ATP 2+ in DBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-proportionality ATP 5+ to ATP 2+ in DBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased therapy participation
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Victorian Institute of Sport Assessment (VISA) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum tolerated dose (MTD) of BAY1143572
Endpoint domain: Physiological/clinical
Primary endpoint: Cumulative Incidence of Aldosterone Breakthrough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in total Kidney Volume (tKV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cognitive and psychomotor status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Relation SpO2-PaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Retrovirus or Leukemia
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal Level of Tumor Necrosis Factor Alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Incivility in Nursing Education Revised Survey score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage change in left ventricular mass index relative to height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in knowledge of ACP
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in self-efficacy concerning ACP
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Roll-over shape
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instantaneous radius of curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with more than 20% diminution of AMH logarithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Nasal carriage of virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Morbi-mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in postprandial glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients submitted to blood components transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in drug consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in permanent canine tooth position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profiles of growth hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability assessed via AEs/SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Vital signs (blood pressure and pulse rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pre-dialysis serum phosphate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with no Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Clinically Significant Laboratory Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinically Significant Vital Signs Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Clinically Significant Abnormalities in Physical Examination Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration V81444
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% brain A2A receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of MAE Free Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral blood flow response to glucose ingestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Blood Glucose Area Under the Curve (AUC 0-6h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean AUC0-24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar Facial Bone regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Without Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Bone Mineral Density at the lumbar spine and femoral neck region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bilirubin serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of oral 6R-BH4
Endpoint domain: Adverse events/effects
Primary endpoint: wear time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events at all visits
Endpoint domain: Adverse events/effects
Primary endpoint: vaccine site evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: laboratory parameters pre and post vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red blood cell cobalamin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Polyneuropathy grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulmonary toxicity grade 2-4
Endpoint domain: Adverse events/effects
Primary endpoint: Esophageal toxicity grade 2-4
Endpoint domain: Adverse events/effects
Primary endpoint: Bone Density of Proximal Femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in skin changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: size of involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of ELLIPTA Doses Taken (Daily Adherence)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of PD1+ CD4 T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Performance of Each Provider on Clinical Indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score during mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: mean gingival index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contribution of FDG-PET/CT in diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HIV/STI Risk Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Removal of myoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Sexual Pleasure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percentage of death regardless of cause
Endpoint domain: Mortality/survival
Primary endpoint: percentage of unplanned hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: percentage of emergency department visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percentage of institutionalization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Glucose and lipid metabolism abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Liver function abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleeping tendency assessment
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Autonomic Nervous System Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: drug levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Any Hypoglycemic Event
Endpoint domain: Adverse events/effects
Primary endpoint: Acute rectal side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Successful Completion of Treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Complete response rate (CR and CRp)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients With Plasma HIV RNA <50 Copies/mL at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Patients With Clinical Adverse Experiences (CAEs) Through 24 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Percent Change From Baseline in Fasting Serum Cholesterol at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUCt) of Guaifenesin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement of gastroparesis based on GCSI-DD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Neuron specific enolase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Capacity of non-invasive biomarkers and intragraft gene expression profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point prevalence by self report
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point prevalence by self report, validated by biochemical measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety/tolerability based on adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of ICAR30 T cells
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Confirmed Best Objective Response (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Thickness of Compacted Myocardial Tissue (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thickness of Non-compacted Myocardial Tissue (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial Fractal Dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drug intervention complications
Endpoint domain: Adverse events/effects
Primary endpoint: Threshold of the 18FDG retention index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prognostic and predictive histopathologic characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crude and adjusted rate of overdiagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between awareness and knowledge of overdiagnosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Difference in Acceptance and Action Questionnaire-II (AAQII)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Difference in Positive and Negative Affect Scale (PANAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Difference in Posttraumatic Stress Disorder Checklist (PCL)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Difference in Beck Depression Inventory (BDI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Difference in Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient satisfaction with successful Essure procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complications of Essure procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Early and Intermediate Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: clinical efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Pressure-volume Area (PVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline to Week 8 in DSST (Number of Correct Symbols)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline to Week 8 in RAVLT (Acquisition and Delayed Recall)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prostate-Specific Antigen (PSA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24h post-operative VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rowing performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of procedural adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious adverse events within 7 days of procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious adverse events > 7 days after the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious adverse events > 30 days after the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Complete electrical isolation of all pulmonary veins (entrance block)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AF termination targeting driver regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of adverse drug reaction (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 Meter Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Pneumothorax after biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of right-sided retroflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recurrence rate of abnormal liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Achieved Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of bladder stimulation for urine collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in post-exercise fall in expiratory flows
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Free Radical Concentration in Muscle Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the ability to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in total number of days with satisfying sexual events
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement of nocturnal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient Movements Affecting Procedure Performance and Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of surgery without narcotics or anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Difference in peak epinephrine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Validation of an ICF core Set for Systemic sclerosis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in HAM-D Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in hemoglobin A1c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes